Praxis Precision Medicines (PRAX) Net Cash Flow (2019 - 2026)

Praxis Precision Medicines' Net Cash Flow history runs 8 years deep, the most recent figure standing at $179.0 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 459.41% year-over-year to $179.0 million in Q1 2026; TTM through Mar 2026 was $370.8 million, a 2628.83% increase from a year earlier, with the FY2025 full-year figure at $142.0 million, up 5.88% from the prior year.
• Net Cash Flow eased to $179.0 million in Q1 2026 per PRAX's latest filing, from $207.8 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $207.8 million in Q4 2025 and bottomed at -$61.4 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$825000.0 (2022), against an average of $23.4 million.
• Across the five-year window, Net Cash Flow slumped 2298.18% in 2023 and surged 459.41% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at -$825000.0 in 2022, then slumped by 2298.18% to -$19.8 million in 2023, then surged by 336.17% to $46.7 million in 2024, then soared by 344.72% to $207.8 million in 2025, then retreated by 13.86% to $179.0 million in 2026.
• Per Business Quant, the three latest PRAX Net Cash Flow figures stand at $179.0 million (Q1 2026), $207.8 million (Q4 2025), and -$7.9 million (Q3 2025).